Amjevita (adalimumab-atto) is a prescription drug used for certain inflammatory conditions, including rheumatoid arthritis and ulcerative colitis. Amjevita can cause side effects that range from mild ...

Since the late 1990s, multiple biologic drugs have been approved to help people with ulcerative colitis (UC) and Crohn’s disease achieve and maintain remission. This includes biosimilars, which are ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa (HS ...

As Humira biosimilars enter the market, patient education about biosimilars is crucial to prevent the nocebo effect when patients switch from the reference product, explained Laura Wingate, executive ...

Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...

Biosimilars for adalimumab (Humira) had similar efficacy and safety profiles for psoriasis when compared to the original. The meta-analysis appeared recently in the Journal of Dermatological Treatment ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy while on prednisone were more likely to have their corticosteroid dose reduced or systemic ...

Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...